- Home
- ICCM vs CELU Comparison
ICCM vs CELU Comparison
Compare ICCM & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- CELU
- Stock Information
- Founded
- ICCM 2006
- CELU 2016
- Country
- ICCM Israel
- CELU United States
- Employees
- ICCM N/A
- CELU N/A
- Industry
- ICCM
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- CELU Health Care
- Exchange
- ICCM Nasdaq
- CELU Nasdaq
- Market Cap
- ICCM 45.5M
- CELU 49.9M
- IPO Year
- ICCM N/A
- CELU N/A
- Fundamental
- Price
- ICCM $1.12
- CELU $2.33
- Analyst Decision
- ICCM Strong Buy
- CELU
- Analyst Count
- ICCM 2
- CELU 0
- Target Price
- ICCM $2.70
- CELU N/A
- AVG Volume (30 Days)
- ICCM 646.4K
- CELU 229.6K
- Earning Date
- ICCM 11-26-2024
- CELU 11-07-2024
- Dividend Yield
- ICCM N/A
- CELU N/A
- EPS Growth
- ICCM N/A
- CELU N/A
- EPS
- ICCM N/A
- CELU N/A
- Revenue
- ICCM $3,671,000.00
- CELU $48,200,000.00
- Revenue This Year
- ICCM $18.61
- CELU N/A
- Revenue Next Year
- ICCM $54.91
- CELU $233.89
- P/E Ratio
- ICCM N/A
- CELU N/A
- Revenue Growth
- ICCM 26.02
- CELU 225.94
- 52 Week Low
- ICCM $0.48
- CELU $1.30
- 52 Week High
- ICCM $1.57
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- ICCM 75.27
- CELU 49.24
- Support Level
- ICCM $0.79
- CELU $2.16
- Resistance Level
- ICCM $1.19
- CELU $2.43
- Average True Range (ATR)
- ICCM 0.08
- CELU 0.26
- MACD
- ICCM 0.03
- CELU 0.00
- Stochastic Oscillator
- ICCM 84.44
- CELU 64.37
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.